Quantcast

Latest Lucentis Stories

2008-07-12 00:00:29

Three elderly patients have launched a landmark High Court challenge over an NHS trust's "absolutely ridiculous" refusal to fund potentially sight-saving treatment. Backed by the Royal National Institute of Blind People (RNIB), they are asking a judge to rule that Warwickshire healthcare chiefs acted "unlawfully and irrationally" in refusing to pay for the drug Ranibizumab, better known under its trade name Lucentis, which is available elsewhere. The sight of all three is threatened by...

2008-06-26 09:03:12

WALTHAM, Mass., June 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Genentech/Novartis's Lucentis will become the Decision Resources' proprietary clinical gold standard by 2011 because of its ability to generate higher total sales in the United States and Europe due to its higher price. Although ophthalmologists perceive Lucentis as offering comparable efficacy to the current clinical...

2006-08-29 08:24:22

By Sam Cage ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50. The U.S. Food and Drug Administration has already approved Lucentis, a drug developed by U.S. firm Genentech Inc., to treat vision loss from the so-called "wet," or more severe form of age-related macular degeneration (AMD). Genentech has the commercial...

2006-08-29 05:04:54

By Sam Cage ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50. The U.S. Food and Drug Administration has already approved Lucentis, a drug developed by U.S. firm Genentech Inc., to treat vision loss from the so-called "wet," or more severe form of age-related macular degeneration (AMD). Genentech has the commercial...

2006-06-30 19:20:42

By Lisa Richwine WASHINGTON (Reuters) - A Genentech Inc. drug that reversed vision loss in some patients won U.S. approval on Friday for treating the leading cause of blindness in the elderly. Injected into the eye monthly, the drug Lucentis maintained vision in 95 percent of patients with the wet form of age-related macular degeneration (AMD) who were treated for 12 months. Eyesight improved in one-third of patients, the Food and Drug Administration said. "The 95 percent retention...

2005-07-18 11:59:19

NEW YORK (Reuters) - Genentech Inc. on Monday said the average patient with age-related macular degeneration who received its experimental drug Lucentis could read an additional seven letters of a reading chart, compared with a vision loss of 10.5 letters among those who received sham injections. The favorable difference, amounting to about 17 letters, was seen in a one year-trial, whose results were presented by researchers at a medical meeting in Montreal. Genentech has said that U.S....


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related